Paul C. Grint, M.D.

Paul Grint is the President of Cerexa. Dr. Grint has significant experience in anti-infective, oncology, and inflammation research and clinical development in both domestic and international markets. Prior to joining Cerexa, Dr. Grint was a Senior Vice President at Forest Research Institute, Inc., a subsidiary of Forest Laboratories, Inc. Prior to joining Forest Laboratories, Dr. Grint was the Chief Medical Officer at Kalypsys Inc., a biopharmaceutical company based in San Diego, California. Before joining Kalypsys, Dr. Grint served as a Senior Vice President and Chief Medical Officer of Zephyr Sciences, and has previously held similar positions at Pfizer La Jolla, IDEC Pharmaceuticals, and Schering-Plough Research Institute (SPRI). Dr. Grint received his Bachelor’s degree from St. Mary’s Hospital, London, and his medical degree at University of London, St. Bartholomew's Hospital Medical College, and is a Fellow of the Royal College of Pathologists.

Ian A. Critchley, Ph.D.

Ian Critchley is the Vice President of Clinical Microbiology at Cerexa. Dr. Critchley joined Cerexa in June 2008, bringing more than 20 years of experience in antibacterial drug discovery and development. Prior to joining Cerexa, Dr. Critchley was Executive Director of Microbiology at Replidyne, where he led a team responsible for all pre-clinical and clinical microbiology studies on antibacterial agents in the development pipeline. Dr. Critchley came to Replidyne from Focus Technologies (now Eurofins Medinet) where he was Director of Laboratory Services. There he established a microbiology laboratory that provides contract research services to evaluate new agents in IND- and NDA-enabling studies and monitors resistance in global surveillance studies. Prior to joining Focus Technologies, Dr. Critchley was a Senior Investigator and Group Leader in Microbiology Research at SmithKline Beecham Pharmaceuticals where he led discovery research groups in both the U.K. and Philadelphia. Dr. Critchley holds a Ph.D. in Microbiology from the University of Glasgow, Scotland, U.K. and a B.Sc. (Hons) in Microbiology from University College, Cardiff, Wales, U.K. Dr. Critchley is a member of the American Society for Microbiology, the U.K. Society for General Microbiology and the British Society for Antimicrobial Chemotherapy.

David Friedland, M.D., M.B.A.

David Friedland is the Vice President of Clinical Sciences at Cerexa. Dr. Friedland joined Cerexa in June 2008 and has extensive experience in the study of infectious diseases, encompassing both academia and the pharmaceutical industry. Prior to joining Cerexa, Dr. Friedland was Senior Director of Clinical Research at Theravance from 2005, where he was responsible for the hospital-acquired pneumonia program and a major contributor to the NDA for telavancin, a gram-positive antibacterial agent. Dr. Friedland came to Theravance from Migenix, a biopharmaceutical company in Vancouver, BC, where he developed antibacterial and antiviral agents. Dr. Friedland served in various positions over an eight year period, most recently as Vice President, Clinical and Medical Affairs. Dr. Friedland obtained his M.D. and Master of Medicine (Microbiology) degree from the University of the Witwatersrand, Johannesburg, South Africa. He also holds an M.B.A. from Queens University, ON, Canada and is a Fellow of the Infectious Diseases Society of America.

Jon Lee

Jon Lee, Vice President of Clinical Operations, joined Cerexa in June 2006. Mr. Lee served in positions of increasing responsibility at Nektar Therapeutics/Inhale Therapeutic Systems, Inc. from 1999 until joining Cerexa. Prior to Nektar, he held various positions within Clinical Operations at Gilead Sciences and Genentech, Inc. Mr. Lee has developed and managed departments and interdisciplinary project teams in each discipline of drug development in therapeutic areas including infectious disease, oncology, neurology, and pulmonology. Mr. Lee graduated from the University of Illinois with a B.S. in Chemistry.

Trisha Dobson, M.B.A., P.M.P.

Trisha Dobson is the Executive Director of Project Management at Cerexa. Ms. Dobson was part of the team that founded Cerexa and currently heads the Project Management function. Ms. Dobson has worked in many stages of development throughout her career and leads the product team for a key antibiotic product. Prior to Cerexa, Ms. Dobson held positions in Project Management at Peninsula Pharmaceuticals. Before working at Peninsula Pharmaceuticals, Ms. Dobson developed and directed the Project Management department at Cerus, instituting a number of key business and strategic management tools. She has been in the industry for more than 15 years, working in both the pharmaceutical and diagnostic environments, and has held key roles on a number of international projects. Ms. Dobson received a B.S. from Case Western University and holds an M.B.A. from St. Mary’s University. Ms. Dobson is a certified P.M.P. (Project Management Professional).

Kristina Haeckl, RAC

Kristina Haeckl is the Executive Director, Regulatory Affairs at Cerexa. Ms. Haeckl has extensive experience in the development and implementation of new drugs and products in the biotech and pharmaceutical industry. Her experience includes interactions with both domestic and international regulatory agencies and she has been involved with complex industry strategic partnerships. Ms. Haeckl has held positions of increasing responsibility over the last twenty years. Most recently, Ms. Haeckl was the Senior Director, Regulatory Affairs and Quality Systems at MAP Pharmaceuticals. Prior to MAP, she was the Director of Regulatory Sciences at Replidyne. Ms. Haeckl has also held regulatory positions at Allos Therapeutics, Inc., OSI Pharmaceuticals (formerly Gilead and NeXstar), Cortech, Inc., and Syntex USA. She was the founder of Kristina Haeckl and Associates and served as Principal Consultant. Ms. Haeckl holds a BA in Environmental, Population, and Organismic Biology from the University of Colorado at Boulder and has achieved Regulatory Affairs Certification (RAC) through the Regulatory Affairs Professional Society.